PDEF and survivin: cancer prognosis, initiation, progression and metastasis
PDEF 和生存素:癌症预后、起始、进展和转移
基本信息
- 批准号:7871433
- 负责人:
- 金额:$ 33.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-08 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAdenocarcinomaAdultAnimal ModelAnimalsBiological MarkersBreast Cancer CellCancer PrognosisCell ProliferationColorectalDataDiagnostic Neoplasm StagingDietary ComponentDown-RegulationDrug toxicityEctopic ExpressionGrowthHumanIn VitroInhibition of ApoptosisIslandKnowledgeLegal patentLifeLuciferasesMCF7 cellMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of prostateMediatingMedicineMethylationMitoticMolecularMusNeoplasm MetastasisNormal tissue morphologyPatientsPharmaceutical PreparationsPlayPreventivePrognostic MarkerProstateProstatic NeoplasmsProteinsRecurrenceRecurrent diseaseRelapseResearch DesignResveratrolRetinoidsRoleScreening procedureSeleniumSulindacTestingTherapeutic EffectTimeTissuesTranscription factor genesTransgenic OrganismsTumor SuppressionTumor Suppressor ProteinsUp-RegulationVirusVitamin Dbasecancer cellcancer initiationcancer recurrencecarcinogenesiscell motilityclinical applicationin vivoinhibitor/antagonistmouse modelnovelnovel strategiesovarian neoplasmpromoterradiation resistanceresponsesilibininsurvivintranscription factortumortumor growthtumor initiationtumor progressiontumor xenografttumorigenesis
项目摘要
Our data indicate that the human prostate-derived Ets transcription factor (PDEF) plays an essential role in tumor suppression via downregulation of the expression of antiapoptotic protein survivin. Ectopic expression of PDEF in PDEF-negative breast cancer cells inhibits survivin expression as well as its promoter activity. In contrast, knockdown of PDEF in PDEF-positive breast cancer cells upregulates survivin expression along with increased cell proliferation in vitro, and increases xenograft tumor take rate and tumor growth in vivo. Importantly, patients with survivin-/PDEF+ tumor show better survival and less relapse than patients with survivin+/PDEF- tumor. Abnormal inhibition of apoptosis is known to be one of the critical steps for oncogenesis and malignant progression. Although the underlying mechanisms are not fully understood, evidence indicates that survivin plays an important role in the initiation, progression, metastasis and recurrence of cancer. Accordingly, many natural dietary components, including resveratrol, silibinin, sulindac, retinoid, selenium and vitamin D compounds that have cancer-preventive and therapeutic effects, downregulate survivin expression. PDEF appears to have an opposing role to survivin and likely via downregulation of survivin expression. It has been shown that PDEF inhibits cancer cell migration, invasion and growth. Based on these observations, we hypothesize that application of survivin and PDEF as interconnected biomarkers and targets to stratify patents with survivin+/PDEF- tumor and patients with survivin-/PDEF+ tumor may facilitate prostate cancer prognosis and personalized medicine. Two specific aims are proposed to test this hypothesis: 1) determine survivin and PDEF expression status and their association with patient survival, cancer metastasis and tumor relapse using prostate cancer tissues; and 2) determine methylation status of the PDEF gene in prostate cancer tissues and its association with the expression of PDEF and survivin. These studies may provide novel approaches for cancer prognosis and personalized medicine, by considering survivin and PDEF as interconnected biomarkers and targets.
我们的数据表明,人前列腺衍生的Ets转录因子(PDEF)通过下调抗凋亡蛋白生存素的表达在肿瘤抑制中起着至关重要的作用。PDEF阴性乳腺癌细胞中PDEF的异位表达抑制了生存素的表达及其启动子活性。相反,PDEF阳性乳腺癌细胞中PDEF的敲低上调存活素表达沿着体外细胞增殖的增加,并增加体内异种移植肿瘤发生率和肿瘤生长。重要的是,存活素-/PDEF+肿瘤患者比存活素+/PDEF-肿瘤患者显示出更好的存活率和更少的复发。细胞凋亡的异常抑制是肿瘤发生和恶性进展的关键步骤之一。尽管其潜在的机制尚未完全清楚,但有证据表明生存素在癌症的发生、发展、转移和复发中起重要作用。因此,许多具有癌症预防和治疗作用的天然膳食组分,包括白藜芦醇、水飞蓟宾、舒林酸、类维生素A、硒和维生素D化合物,下调存活素表达。PDEF似乎具有与存活素相反的作用,并且可能通过下调存活素表达。研究表明,PDEF可抑制癌细胞迁移、侵袭和生长。基于这些观察结果,我们假设,应用生存素和PDEF作为相互关联的生物标志物和靶点,对生存素+/PDEF-肿瘤患者和生存素-/PDEF+肿瘤患者进行分层,可能有助于前列腺癌预后和个性化治疗。提出了两个具体目的来检验该假设:1)使用前列腺癌组织确定存活素和PDEF表达状态及其与患者存活、癌症转移和肿瘤复发的关联;和2)确定前列腺癌组织中PDEF基因的甲基化状态及其与PDEF和存活素表达的关联。这些研究可能为癌症预后和个性化医疗提供新的方法,通过考虑生存素和PDEF作为相互关联的生物标志物和靶标。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry.
- DOI:10.18632/oncotarget.1599
- 发表时间:2014-01-15
- 期刊:
- 影响因子:0
- 作者:Ambrosone CB;Young AC;Sucheston LE;Wang D;Yan L;Liu S;Tang L;Hu Q;Freudenheim JL;Shields PG;Morrison CD;Demissie K;Higgins MJ
- 通讯作者:Higgins MJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Fengzhi Li其他文献
Fengzhi Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Fengzhi Li', 18)}}的其他基金
A novel regimen to target both pancreatic cancer K-ras and antiapoptotic proteins
一种针对胰腺癌 K-ras 和抗凋亡蛋白的新疗法
- 批准号:
8786875 - 财政年份:2014
- 资助金额:
$ 33.9万 - 项目类别:
An inhibitor of multiple anti-apoptotic gene products for pancreatic cancer
多种胰腺癌抗凋亡基因产物的抑制剂
- 批准号:
8890729 - 财政年份:2014
- 资助金额:
$ 33.9万 - 项目类别:
An inhibitor of multiple anti-apoptotic gene products for pancreatic cancer
多种胰腺癌抗凋亡基因产物的抑制剂
- 批准号:
8694557 - 财政年份:2014
- 资助金额:
$ 33.9万 - 项目类别:
A novel regimen to target both pancreatic cancer K-ras and antiapoptotic proteins
一种针对胰腺癌 K-ras 和抗凋亡蛋白的新疗法
- 批准号:
8616128 - 财政年份:2014
- 资助金额:
$ 33.9万 - 项目类别:
A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer
一种治疗癌症的小分子广谱抗凋亡基因抑制剂
- 批准号:
8647283 - 财政年份:2014
- 资助金额:
$ 33.9万 - 项目类别:
PDEF and survivin: cancer prognosis, initiation, progression and metastasis
PDEF 和生存素:癌症预后、起始、进展和转移
- 批准号:
7730215 - 财政年份:2009
- 资助金额:
$ 33.9万 - 项目类别:
Survivin expression and cancer cell drug resistance
Survivin表达与癌细胞耐药性
- 批准号:
7081300 - 财政年份:2004
- 资助金额:
$ 33.9万 - 项目类别:
Survivin expression and cancer cell drug resistance
Survivin表达与癌细胞耐药性
- 批准号:
6817505 - 财政年份:2004
- 资助金额:
$ 33.9万 - 项目类别:
Survivin expression and cancer cell drug resistance
Survivin表达与癌细胞耐药性
- 批准号:
7392643 - 财政年份:2004
- 资助金额:
$ 33.9万 - 项目类别:
Survivin expression and cancer cell drug resistance
Survivin表达与癌细胞耐药性
- 批准号:
7231471 - 财政年份:2004
- 资助金额:
$ 33.9万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 33.9万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 33.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 33.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 33.9万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 33.9万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 33.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 33.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 33.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 33.9万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 33.9万 - 项目类别:














{{item.name}}会员




